Immunotherapies in Non-Small Cell Lung Cancer
Immunotherapy recommendations for patients with thoracic cancers are rapidly changing, and health care providers are challenged to remain aware of the most current recommendations in the NCCN Guidelines® to improve outcomes for their patients.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentations from the NCCN 2019 Congress Series™: Lung Cancer
The American Cancer Society (ACS) estimates that 228,150 new cases of lung cancer will be diagnosed in the United States in 2019 with an estimated 142,670 estimated deaths, with smoking remaining an important risk factor.  The emergence of new biomarker testing, advances in radiation techniques,
Category
Format
Credits
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lung Cancer
For each of the emerging therapies described (bevacizumab, PARP inhibitors, and HIPEC), the treatment settings, patient selection criteria, and other therapies used in conjunction have varied widely across clinical trials. This has led to much discussion and likely confusion regarding the exact clinical contexts in which these new options should be considered.
Category
  • Lung Cancers
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date February 27, 2020
Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: New Treatments for Metastatic Lung Cancer
The new combination immunotherapy + chemotherapy regimens represent a major change in systemic therapy for patients with metastatic NSCLC. Case managers and other health care providers have less experience with these new immunotherapy + chemotherapy regimens or the newer targeted therapies that have different mechanisms of action and side effects than traditional cytotoxic chemotherapy regimens.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents
The goal of this program is to improve the knowledge and competence of clinicians to implement best practices in the treatment of CLL. Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Collaborative Strategies to Ensure Optimal Application of the Latest Treatment Approaches in Hepatocellular Carcinoma
The goal of this activity is to improve participants’ competence in applying the latest treatment approaches and interdisciplinary collaborative strategies towards optimal care of patients with hepatocellular carcinoma.
Category
  • Hepatocellular Carcinoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Expert Insights on New Systemic Therapies for Advanced Prostate Cancer
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating recent findings into the treatment of patients with prostate cancer. 
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
AML: Expert Guidance on Current Standards and New Directions in Patient Care
The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current best practices in the treatment of AML. Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentations from the NCCN 2019 Annual Congress: Hematologic Malignancies™
Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.
Category
Format
  • Enduring Activity
  • Recorded Webcast
Credits
NCCN Guidelines® Insights - Hematopoietic Growth Factors, Version 1.2020
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN.
Category
  • Myeloid Growth Factors
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages